Enseifentrine (ensifentrine)-Ohtuvayre price and formal purchase channels

Ensifentine Inhalation Suspension Solution (Ensifentrine)-Ohtuvayre is a new type of chronic obstructive pulmonary disease (COPD) inhalation drug. It has not yet been officially launched in China. Therefore, the price, medical insurance coverage and formal purchase channel information in the domestic market are not yet clear. There may be news of the drug being launched in small quantities in some administrative regions, but overall accessibility is limited. In overseas markets, the U.S. version of the original drug is 3mg/2.5mL (60 doses), and each box sells for about more than 40,000 yuan. However, the price will vary due to fluctuations in exchange rates, taxes, and regional pricing policies. This price level reflects the comprehensive factors of high R&D costs, complex production processes, and clinical efficacy value of monoclonal dual-target drugs.

There are currently no generic versions of exefantine inhalation suspension on the market, which means that if patients need to use the drug, they must obtain the original product through formal medical channels. In overseas clinical practice, obtaining the drug usually requires a doctor's prescription and professional pharmacy distribution to ensure drug quality and patient safety. Since inhaled drugs have strict requirements for storage and transportation conditions, including temperature, light, and expiration date management, procurement through informal channels involves unstable drug efficacy and safety risks, which may affect the therapeutic effect and increase the risk of adverse reactions.

It is worth noting that ensefentin is a long-term maintenance treatment drug for COPD, and its economic cost is relatively high. In overseas markets, patients usually need to combine medical insurance policies, patient assistance programs or clinical trial projects to reduce the burden of treatment. This strategy not only ensures that patients receive scientific treatment plans, but also ensures the safety and sustainability of drug use.

Generally speaking, the price of exefantine in the international market is relatively high and it is not yet available in the country. The formal purchase channels mainly rely on doctors’ prescriptions and certified pharmacies. In future clinical practice, the economy and accessibility of drugs will become important reference factors for COPD patients to choose treatment options. At the same time, ensuring the quality and safety of drugs is the key to rational use.

Reference materials:https://www.drugs.com/monograph/ensifentrine.html